_256_384.jpg)
Drug Approval | October 12, 2021
Covaxin for kids gets nod, final approval awaited
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
It recommends using the vaccine to prevent the spread of the disease
Early-stage research suggests the potential to prevent and treat all dengue serotypes and builds on Johnson & Johnson's work to advance science against emerging and entrenched global public health threats
A growing number of studies have shown the benefit of a third dose of Covid-19 vaccine in immunocompromised subjects
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
India’s first gender-neutral HPV vaccine to help reduce HPV -related disease burden in Indian girls, women and boys
The Mission will simplify hospital processes and will increase Ease of Living. Under this, every citizen will get a digital health ID and their health record will be digitally protected.
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
Subscribe To Our Newsletter & Stay Updated
